Phase 1/2 trial of ONCT-534 in mCRPC has been terminated - Urology Times
2024-11-07 • Google News
Oncternal Therapeutics Inc (ONCT)
US$ 0.71-37.71%
Price Chart
Key Statistics
Market Cap
$ 1.56M
P/E Ratio
0.00
Revenue (TTM)
$ 2.16M
Volume
797.68K
52W High
$ 6.00
52W Low
$ 0.53
Dividend Yield
0.00%
Beta
1.33
Technicals
50-Day MA
0.5266
200-Day MA
1.5464
52 Week High
6
52 Week Low
0.5266
About ONCT
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs.
Employees
27
Headquarters
San Diego, CA
CEO
Dr. James B. Breitmeyer M.D., Ph.D.
Latest News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg